Medical researchers have reported a significant breakthrough in stroke treatment, demonstrating that a new drug may extend the critical treatment window from six hours to 48 hours after symptom onset, potentially improving recovery outcomes for many patients.
In a large-scale, multicenter phase 3 clinical trial published on September 10 in the Journal of the American Medical Association, the drug loberamisal was shown to enhance the likelihood of complete functional recovery in acute ischemic stroke patients treated within two days of their stroke. The study involved 998 patients across 32 hospitals in China who had experienced moderate to moderately severe strokes marked by symptoms such as hemiplegia, aphasia, visual field defects, or decreased consciousness.
Participants were randomly assigned to receive either 10 days of intravenous loberamisal or a placebo, in addition to standard stroke care. At 90 days post-treatment, 70 percent of patients in the loberamisal group achieved full functional independence, a 13.4 percentage point increase compared to the placebo group. This improvement means these patients were able to resume daily activities without significant disability.
The lead researcher, Wang Yongjun, vice-president of Beijing Tiantan Hospital and director of its neurology center, highlighted that the drug appears to protect and repair brain cells by reducing excitability and blocking damaging processes such as neuroinflammation and oxidative stress. Loberamisal's neuroprotective action helps to preserve ischemic brain tissue that is injured but not yet irreversibly damaged, mitigating the severity of stroke-related impairments.
Previous efforts to develop neuroprotective stroke therapies in Canada, the United States, and Japan have largely been unsuccessful in clinical trials, making these findings particularly notable. The trial’s safety data indicated no significant difference in the incidence or type of adverse effects between the treatment and placebo groups, suggesting that loberamisal is well tolerated.
Jeffrey Sayer, a neurologist and associate editor of the journal, emphasized the importance of the study in an editorial accompanying the publication. He noted that despite more than seven decades of testing various neuroprotective agents with consistent failure, the positive results reported for loberamisal may represent a turning point in stroke treatment research.
The expanded treatment window offered by loberamisal could potentially transform acute ischemic stroke management by allowing a broader population of patients to receive effective therapy beyond the current six-hour limit, thereby reducing disability and enhancing recovery prospects. Further studies and regulatory review will be necessary before the drug can be widely adopted in clinical practice.